HOME >> MEDICINE >> NEWS
AMN107 has potent activity in leukemia resistant to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center (meeting abstract #37).

At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in outcome in all three phases of chronic myeloid leukemia (CML) as well as benefit in treating a form of acute lymphocytic leukemia (ALL) that shares the same genetic abnormality as CML, the Philadelphia chromosome.

"This drug is very promising and appears at this point to offer an effective option for patients who do not achieve an optimal response to Gleevec therapy," says Hagop Kantarjian, M.D., professor and chair of the Department of Leukemia.

If additional studies continue to show such results, Kantarjian says, he believes AMN107, which is taken in pill form, "will either replace Gleevec as the standard of care in the future or will be used in combination with it."

Both CML and Philadelphia-positive ALL is caused by the swapping of genetic material in bone marrow stem cells between two chromosomes, which produces an abnormality called the Philadelphia chromosome. This new gene then produces a novel tyrosine kinase (Bcr-Abl) that signals the abnormal cell growth that leads to development of leukemia.

While both Gleevec and AMN107 shut down the activity of Bcr-Abl, laboratory experiments with AMN107 show it is up to 50 times more potent because it binds more efficiently to the enzyme than does Gleevec.

In the phase I clinical trial being reported, 119 patients who were resistant to Gleevec were given AMN107, and in some cases the dose was increased up to twelve fold. The researchers found that the range of response varied, depending on the form of the cancer and the presence of genetic mutations. For example, hematologic response fr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
10-Dec-2005


Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Electric fields have potential as a cancer treatment
3. STAMP system can help professionals to identify potentially violent individuals
4. AMPAKINE compounds a new potential treatment for respiratory depression
5. Herb shows potential to reduce cancer-related fatigue
6. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
7. Women with breast cancer do not get potentially life-saving information, survey reveals
8. Eating cured meats frequently can lead to lower lung function and potential COPD
9. Clinical studies evaluate potential treatments for mouth ulcers
10. Synthetic production of potential pharmaceuticals dramatically simplified by Scripps research team
11. Obesity and environmental chemicals -- New research probes potential link

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AMN107 has potent activity leukemia resistant Gleevec

(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... Drug Administration (FDA) has issued a Complete Response ... AVP-825. AVP-825 is an investigational drug-device combination product ... a novel Breath Powered delivery technology. ... with the preliminary feedback announced on November 7, ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: